USA – Thermo Fisher Scientific’s PPD clinical research business and Matrix Clinical Trials, a division of Matrix Medical Network, have formed a partnership to provide clinical trials to patients through a new decentralized clinical trial (DCT) solution.

By deploying Matrix mobile research sites and skilled clinical staff across the United States, the company will aid in the identification, recruitment, and retention of trial subjects while ensuring a positive participant experience.

Simultaneously, the parties are looking into ways to expand the partnership into new areas.

Thermo Fisher’s clinical research division is the only clinical research organization (CRO) that uses Matrix’s virtual principal investigator network and mobile sites as a standalone transportable clinical trial operation.

The collaboration demonstrates Thermo Fisher’s ongoing commitment to advancing decentralized trial solutions for clients and patients.

Thermo Fisher clinical research digital and decentralized solutions vice-president Tim Rich said: “Mobile sites are a key component of our sought-after portfolio of hybrid and decentralized clinical trial capabilities.

With Matrix’s experienced teams of clinicians and ready-to-deploy mobile sites, we are able to reach a broader range of participants, including in previously under-represented and under-served communities, without requiring them to travel to traditional investigator sites far from their homes.”

The clinical research industry provides adaptable decentralized trial solutions developed across a wide range of therapeutic areas.

The goal is to increase the diversity of subjects and access, as well as to improve the patient experience, resulting in time savings and data quality improvements that can help to accelerate development timelines.

These services reduce the burden on patients to participate in trials while providing customers with increased geographic reach through reduced reliance on brick-and-mortar site locations, immediate access to data, improved quality and consistency, and improved patient engagement.

Meanwhile, Thermo Fisher Scientific has released the new Gibco CTS TrueCut Cas9 Protein, which is manufactured in accordance with GMP standards.

TrueCut Cas9 proteins are produced in accordance with US Pharmacopeia standards, including traceability documentation, aseptic manufacturing, and safety testing.

Gibco CTS TrueCut Cas9 Protein exhibits consistent high editing efficiency in all tested cell lines and greater than 90% efficiency in human primary T-cells, making it an appealing candidate for CAR T-cell therapy research using CRISPR-Cas9 genome editing.

Thermo Fisher can now support researchers across the autologous T-cell workflow with the addition of a GMP-manufactured Cas9 protein and the recently launched Gibco CTS Xenon Electroporation System.

The Gibco CTS TrueCut Cas9 Protein is a component of Thermo Fisher’s Cell Therapy Systems (CTS) product line, which includes a comprehensive portfolio of GMP-manufactured products backed by traceability documentation.

To meet the manufacturing needs of cell therapy developers, this product line is designed to work synergistically across the entire workflow, from cell isolation/activation to cell engineering and expansion.

Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE